2016
DOI: 10.1007/978-1-4939-3634-2_7
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Cancer Using Nanocarriers

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 151 publications
0
2
0
Order By: Relevance
“…Nanogels with a mean diameter of approximately 200 nm were prepared by cross-linking of thiolated Hep, followed by induction of glutathione-mediated release of Hep, which lead to the inhibition of cancer cell proliferation (Bae et al, 2008). Moreover, HA was conjugated to lipid-based NP for the specific delivery of siRNA to cancer cells that overexpress CD44, to induce gene silencing (Landesman-Milo et al, 2013). Physically formed NP of chitosan and CS were used successfully for the release of platelet lysate, which represents a promising system for bone-TE (Santo et al, 2012).…”
Section: Glycosaminoglycans As a Component Of Micro-and Nanoparticlesmentioning
confidence: 99%
“…Nanogels with a mean diameter of approximately 200 nm were prepared by cross-linking of thiolated Hep, followed by induction of glutathione-mediated release of Hep, which lead to the inhibition of cancer cell proliferation (Bae et al, 2008). Moreover, HA was conjugated to lipid-based NP for the specific delivery of siRNA to cancer cells that overexpress CD44, to induce gene silencing (Landesman-Milo et al, 2013). Physically formed NP of chitosan and CS were used successfully for the release of platelet lysate, which represents a promising system for bone-TE (Santo et al, 2012).…”
Section: Glycosaminoglycans As a Component Of Micro-and Nanoparticlesmentioning
confidence: 99%
“…One goal of targeted nanomedicine is to construct nanoparticles that do reach their target and release the drug they are carrying at that site, typically in cancerous tissues, so that the cancer can be treated without there being severe systemic side-effects [Singh & Lillard 2009]. Nanoparticle-based drug delivery has the potential of increasing the dose and targeted toxicity of drugs reaching the cancer while protecting healthy cells from their toxic effects [Landesman-Milo, Qassem et al 2016].…”
Section: Introductionmentioning
confidence: 99%